Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 14/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SPR | P35270 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7079006 | 0.90 | MEN1 (0.45) | NR3C1CCR2CCR5KMT2AMEN1 | |
| SCHEMBL7079264 | 0.90 | NR3C1 (0.40) | NR3C1CCR2CCR5SPRPOLB | |
| SCHEMBL7077952 | 0.90 | SPR (0.48) | NR3C1CCR2CCR5KMT2ARAB9A | |
| SCHEMBL7137484 | 0.88 | SPR (0.43) | NR3C1CCR2CCR5NPC1RAB9A | |
| SCHEMBL5961577 | 0.85 | CCR2 (0.51) | NR3C1CCR2CCR5 | |
| SCHEMBL7078063 | 0.84 | SPR (0.40) | NR3C1CCR2CCR5NPC1RAB9A | |
| SCHEMBL5961472 | 0.84 | CCR2 (0.63) | NR3C1CCR2CCR5SPR | |
| SCHEMBL5961522 | 0.84 | CCR2 (0.53) | NR3C1CCR2CCR5SPRPOLB | |
| SCHEMBL5961537 | 0.83 | CCR2 (0.45) | NR3C1CCR2CCR5NPC1RAB9A | |
| SCHEMBL7078734 | 0.83 | POLB (0.41) | NR3C1CCR2CCR5SPRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6670364-B2 | For example (1,3-dimethylpyrazolo(5,4-b)pyridin-5-yl)-N-(((4-fluorophenyl) amino)carbonyl)-carboxamide; useful in prevention or treatment of chronic or acute inflammatory or autoimmune diseases | TELIK, INC. | 2003-12-30 | — | — | US | claimed |
| US-20030096705-A1 | Antagonists of MCP-1 function and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2003-05-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096705-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | NR3C1 673/4885CCR2 1/4885CCR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.